- Pulmonary arterial hypertension:
- <40 kg: Maintain dose at 62.5mg BD. Max: 125mg per day
- >40 kg: 5mg BD *4/52 and then increased to maintenance of 125mg BD. Max 250mg BD
- Reduce dose when discontinuing to 62.5mg BD *3-7 days
- Monitor AST/ALT levels constantly
Tablet:
- 62.5mg
- 125mg
Take with or without food
Competitive antagonist of endothelin-1
It blocks endothelin receptors on vascular endothelium and smooth muscle resulting in inhibition of vasoconstrictive effects of endothelin-1 thereby reducing pulmonary vascular resistance
- URI
- Decreased Hb
- Headache
- Peripheral edema
- Syncope
- Flushing
- Hypotension
- Sinusitis
- Arthralgia
- Elevated ALT/ AST
- Palpitations
- Anemia
- Decreased sperm count
- Hypersensitivity to class/components
- Pregnancy
- ALT or AST >3x ULN
- Hepatic impairment
- Pulmonary veno-occlusive disease
- Anemia
- Avoid abrupt withdrawal
WARNING:
- Risk of hepatotoxicity: Avoid in patients with elevated aminotransferase levels (>3X ULN)
- Negative pregnancy test result required before initiating & prevention of pregnancy required thereafter due to serious birth defects associated with drug
- Artemether/lumefantrine
- Cariprazine
- Cobimetinib
- Cyclosporine
- Dienogest/estradiol valerate
- Doravirine
- Elvitegravir/cobicistat/emtricitabine/tenofovir
- Fostemsavir
- Glyburide
- Isavuconazonium sulfate
- Lonafarnib
- Lorlatinib
- Lumefantrine
- Naloxegol
- Ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)
- Panobinostat
- Praziquantel
- Regorafenib
- Roflumilast
- Vandetanib
Drug Status
Availability | Prescription only |
Pregnancy | Category X |
Breastfeeding | Contraindicated |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Bosetan | 125mg | Tablet | 10’s | Glenmark Pharma | Glenmark Pharma |
Bosetan | 62.5mg | Tablet | 10’s | Glenmark Pharma | Glenmark Pharma |
Pulmofirst | 125 mg | Tablet | 10’s | MSN Labs | Simba Pharma |
Pulmofirst | 62.5mg | Tablet | 10’s | MSN Labs | Simba Pharma |